FIMECS is Named by The 2020 APAC Business Awards as “Best Tech-Based Drug Discovery Biotech – Japan”
News release Download PDF
Kanagawa, Japan, 21, Jan 2021 – FIMECS, Inc. (“FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has been named by The 2020 APAC Business Awards organized by APAC insider as “Best Tech-Based Drug Discovery Biotech – Japan”
Please find the detail below.
APAC Insider Magazine Announces the Winners of the 2020 Business Awards: https://www.apacinsider.com/apac-insider-magazine-announces-the-winners-of-the-2020-business-awards/
FIMECS, Inc. Best Tech-Based Drug Discovery Biotech – Japan: FIMECS, Inc – Japan 2020 (apacinsider.com)
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
# # #
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan